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S  Seminal  studies  K  Key studies  R  Reviews  G  Guidance  MORE  Search for more studies
S  Original  methadone maintenance tria l  (1965). Vincent Dole and Marie Nyswander’s  report paved the way for the world’s  most widespread effective treatment for
opiate addiction.
S  Study seen as  endors ing switch to methadone in Bri ta in (1980). Unique tria l  conducted in London in the early 1970s  randomised patients  seeking injectable
heroin prescriptions  to that or to oral  methadone; results  favoured heroin but not clearly enough to reverse the trend to methadone. See study 1 in l inked PDF fi le.
S  Methadone treatment saves  l ives  in Sweden (1990). Restrictions  on methadone maintenance in Sweden enabled i ts  value to be convincingly demonstrated. The
death rate leapt when maintenance was banned and detox and drug-free treatment took over. Reviewed with other Swedish studies  in The Swedish experience
(2000) on p. 6 of l inked PDF fi le.
K  Lasting benefi ts  but methadone in England could do better (2000 and 2001). Reports  from the 1990s  NTORS study confi rmed that the benefi ts  of methadone
pers ist to two years  after treatment entry, though nearly a  fi fth of patients  did not respond wel l  to often i l l -defined programmes undermined by under-dos ing and
poor ini tia l  assessment.
K  Enriched methadone detoxi fication sti l l  bettered by maintenance (2004). Results  from a US randomised tria l  (2000) which tested whether enriching methadone-
based detoxi fication with intens ive psychosocial  services  and aftercare would enable i t to match minimal-support methadone maintenance. Raw results  were that
after detoxi fication ended, maintenance patients  used i l l i ci t opiates  less  often, had fewer legal  compl ications, and were at lower risk of blood-borne diseases,
trans lating (2004) into an estimated low-cost extens ion of l i fe.
K  Long-acting naltrexone implants  help sustain abstinence (2012). Russ ian study finds  naltrexone implants  preferable to the oral  form of the drug for sustaining
post-detoxi fication abstinence. See also s imi lar Austral ian tria l  (2009). Implants  have also been tried with some success  in Bri ta in.
R  Medications  ease opiate withdrawal  but relapse common (Cochrane review, 2012). Review comparing tapering doses  of methadone to other medications  finds
al l  help complete withdrawal  but most patients  then return to i l legal  opiate use, highl ighting the need for fol low-on treatment.
R  Methadone maintenance on average preferable to detoxi fication (Cochrane review, 2009). A surpris ingly smal l  basket of randomised control led tria ls  (but
confirmed by other studies) supports  the superiori ty of methadone maintenance over detoxi fication for patients  prepared to be al located to ei ther. See also this
later (2014) US-focused review commiss ioned by the US government.
R  Buprenorphine works  but methadone works  better (Cochrane review, 2012). High-dose buprenorphine curbs  i l legal  opiate use but when the two were compared
in randomised tria ls , longer retention meant methadone was on average more effective. See also this  later (2014) US-focused review commiss ioned by the US
government.
R  Drug treatments  for opiate dependence (2010). Draws together findings  from authori tative reviews of rigorous  research conducted for the Cochrane
col laboration and later studies  concerned with the pharmacological  and psychosocial  treatment of dependence on opiates , including withdrawal  and
maintenance.
R  Motivational  interviewing is  for medics  too (2013). Reviews this  popular and often brief counsel l ing approach as  appl ied in medical  care settings  for drug and
non-drug related conditions. Concludes, “i f you can devote a  smal l  amount of extra time with your patients  to bui ld relationship and evoke change talk, you can
expect 10–15% additional  improvement.” Impacts  were on problem drinking and cannabis  use were among the strongest.
R  G  Comprehensive review and guidance from Bri tish Association for Psychopharmacology (2012). Guidance based on l i terature review of evidence for drug-
based treatments  for substance use problems. Covers  a lcohol , nicotine, opioids , benzodiazepines, s timulants , cannabis , ‘club drugs’ and the ‘polydrug’ use of
several  drugs  together, focus ing on dependence rather than ‘harmful  use’ or ‘abuse’. Sections  on mental ly i l l  and personal i ty-disordered patients , chi ldren and
young adults , the elderly, and treatment during pregnancy. This  book provides  a  s imi lar but more extended US-oriented account.
G  UK cl inical  guidel ines  on treating drug problems ([UK] Department of Health and the devolved administrations, 2007). Officia l  guidel ines  currently in force but
being updated. Update l ikely to take in expert cl inical  consensus  ([UK] National  Treatment Agency for Substance Misuse, 2012) on adapting these treatments  to
national  pol icy focused on recovery.
G  Choose substi tute drug on an individual  bas is  (NICE, 2007). UK’s  officia l  health advisory authori ty recommends methadone and buprenorphine for opiate
addiction treatment and says  the choice between them should be based on benefi ts  and risks  for each individual  patient.
G  Use methadone or buprenorphine for withdrawal  (NICE, 2007). UK’s  officia l  health advisory authori ty recommends methadone and buprenorphine for
withdrawing addicts  from opiates  and counsels  against ul tra-rapid methods us ing general  anaesthes ia  or heavy sedation.
G  Substi tute prescribing for opioid dependence in primary care ([UK] Royal  Col lege of General  Practi tioners , 2011). Guidance for Bri tish GPs  on how to withdraw
heroin and other opioid addicts  from opiate-type drugs  or to maintain them by long-term prescribing of legal  substi tutes , with a  focus  on the use methadone and
buprenorphine.
G  How cl inicians  can identi fy and respond to cannabis  use problems ([Austral ian] National  Cannabis  Prevention and Information Centre, 2009). Evidence-based
guidance for a l l  cl inicians  (but especial ly GPs), funded by the Austral ian government. Covers  the range of cannabis  use interventions  from brief advice for users
identi fied by screening through to managing withdrawal  and treating dependence.
MORE  This  search retrieves  a l l  relevant analyses .
For subtopics  go to the subject search page or hot topics  on prescribing opiates , naltrexone implants , and counsel l ing in methadone treatment.
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What is this cell about? About the treatment of dependence on illegal drugs in a medical context and/or involving medical care, typically
by GPs or by drug treatment or psychiatric units in hospitals. Clinical staff are responsible for medications, so the centrality of these to an
intervention distinguishes it most clearly as medical. Medications may be intended to help patients withdraw from drugs more
comfortably and with a greater chance of completing the process, to sustain longer term abstinence (eg, the opiate-blocking drug
naltrexone), or to substitute a safer and medically controlled drug of the same kind more conducive to social stabilisation, such as
methadone for dependent heroin users. But medications are never all there is to medical care. Ideally, they promote a stable space free
of drug effects and/or the need to chase illicit supplies during which patients can find other ways to cope and construct lives
incompatible with a return to dependent illegal drug use. Drug-based treatments also include potentially therapeutic interactions with
clinical and other staff and ways to encourage patients to take medications, sometimes enlisting family and others. Medical treatment
for drug dependence may consist entirely of advice and medical and psychosocial support.
Where should I start? No better introduction than the unusually comprehensive, authoritative and freely available review and guidelines
from the British Association for Psychopharmacology. Here we highlight a feature of the guidelines which may not be immediately
apparent; that in so comprehensively documenting the positive roles of medications, they also throw in to relief their limitations.
Among the illicit drugs, only in respect of dependence on opioid drugs like heroin do the guidelines see medications playing a major and
validated role. Best established are approaches which rather than preventing dependent use, replace one opioid with a legal supply of
the same drug or another which is safer and can form the basis for a life free from crime and reliance on an illicit market. That leaves
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the same drug or another which is safer and can form the basis for a life free from crime and reliance on an illicit market. That leaves
swathes of illicit and/or recreational drug use entirely or largely outside the ambit of drug-based treatments, and dependent users reliant
on treatments based on human interaction.
Nevertheless, hopes and expectations of techno-medical fixes remain high, underpinned by the conviction that addiction is a “disease of
the human brain” characterised by progressive “weakening” of neural circuits caused by repeated drug use, changes which limit addicts’
freedom to choose not to use – the vision presented by the head of the US National Institute on Drug Abuse, by far the world’s largest
addiction research funder. That vision is challenged by estimates that no matter how long ago someone became dependent, their
chances of remission remain the same, seemingly at odds with paradigms which assume addicts become progressively more incapable of
stopping drug use. Instead, it’s argued, addiction results from the same preferences which in everyday life lead people to prioritise short-
term and easy-to-reach (‘low-hanging fruit’) rewards over broader and longer-term benefits.
In the end perhaps, all such explanations fit (even if only at the level of an analogy) some of the people some of the time to some degree.
Like a limp, dependence is recognised by a distinctive behaviour, but that doesn’t mean there is a correspondingly distinct disease entity.
Limps can arise from a poorly fitting shoe, an uneven floor, or a neural disease, be quick or hard to fix, and need different fixes and fixers
– cobblers, carpenters, or doctors. Sometimes all it takes is the intention to walk straight plus a little temporary help, sometimes a
lifetime of support.
Highlighted study What’s best – to maintain heroin addicts on methadone, or use tapering doses to get them free of legal and illegal
opiate-type drugs? In the recovery era in the UK, that is a critical question; influential visions of ‘full’ recovery and payment-by-results
criteria embody the prioritisation of treatment exit, not prolonged maintenance.
Answers founder on the difficulty of creating a level playing field; suitable patients who opt for detoxification differ from those not yet
ready to relinquish opiate-type drugs. Also, the two treatments’ aims differ so widely that comparing them seems as nonsensical as
comparing palliative care with chemotherapy for cancer. Yet in everyday practice, people do come to treatment unsure which route to
take. What happens if you decide this by a flip of the coin? This unique US study from the 1990s pulled off just such a comparison,
recruiting 179 opioid-dependent patients who agreed to be randomly allocated to maintenance or detoxification. Reflecting the difficulty
of finding patients suitable and willing to undertake either of these opposed treatments, most referrals thought eligible for the study
rejected it or turned out to be unsuitable.
The minority who did join the study were allocated to either 14 months of methadone maintenance (the ‘maintenance’ patients) or to just
four months (the ‘detoxification’ patients), both followed by a two-month detoxification when doses were gradually reduced. To help even
the scales, detoxification patients were offered more intensive psychosocial support which continued for another eight months after the
scheduled end of detoxification.
That sets the stage for the findings in this freely available report. First to note is methadone’s holding power, including its power to
engage patients in psychosocial support. Focus on figure 3, showing how retention in treatment fell over time. Note the steep drops as
patients entered the detoxification phases of their treatments, until practically none were left. Nearly half the detoxification patients
were discharged prematurely, usually dropping out as they faced the end of their methadone tapers. Figure 2 shows that in the pre-
detoxification phase, detoxification patients did attend the extra counselling required for them to stay in treatment. But when the
methadone went, so too did the patients, and drug-free aftercare – no longer required to continue to get methadone – was largely
rejected.
Now to figure 4 and the clear pattern in heroin use; steep initial drops which stayed down in the maintained patients but bounced back up
when detoxification patients were tapered from methadone. But that bounce-back still left them using on average about half as often as
they did at the start of the study; not all the gains were reversed. Maintained patients also had the edge in crime and HIV risk.
The researchers’ verdict was pointed: “[no] support for diverting resources from methadone maintenance to long-term detoxification, no
matter how ideologically attractive the notion of a time-limited treatment for opioid abusers.” Is this how you see it? Perhaps, as the
researchers speculated, the extra support was (in today’s language) not recovery-oriented, failing to address legal, employment, family,
and psychiatric issues. And perhaps a halving in illicit heroin use frequency is as good – maybe better depending on your priorities – than
a steeper drop achieved only with the aid of a daily opiate substitute. If one throws illicit heroin and methadone in the same opioid use
bag, frequency of use was probably higher in the maintained patients.
Perhaps the clincher is the estimate that relative to detoxification, maintenance will have saved lives. But perhaps not, if you feel a life
tied to a methadone clinic to daily swallow the drug in front of staff and submit to observed urine tests, yielding control of significant
parts of your life, is not the best of lives. But being back on the streets hustling for illicit heroin is not so grand either, and much more
dangerous. In the end, how you weigh the data from this study depends on your values. Pondering and discussing what you and your
colleagues make of these findings could take you a long way to clarifying those and what for you they mean in practice.
Issues to think about
 Will maintenance ever be accepted? Seems a strong question, but for over a century the misgivings have refused to go away and
seem as sharp as ever. Ironically, the most widespread effective pharmacotherapy for addiction is also the one which most consistently
arouses opposition. In 2014 Pope Francis condemned it as compromising with the “evil” of drugs: “Substitute drugs, moreover, aren’t a
sufficient therapy, but rather a hidden way to surrender ... Simply no to every type of drug.” From more radical perspectives, the treatment
has been castigated as a “Calvinist-Puritanical project of managing immoral pursuits of pleasure and of promoting personal self-control”
– the hobbling of anti-establishment outsiders by chains of dependence harder to break and more damaging than heroin, which force
them to cede control over their lives to authorities they previously challenged, evaded or rejected. Thomas Szasz, a renowned radical
American professor of psychiatry, likened methadone maintenance to “the gas chamber to which the Blacks go as willingly as the Jews
went in Germany.” While methadone weakens or eliminates the get-up-and-go needed to forage for illicit heroin, today’s ‘parking’ jibe
critiques the treatment for also undermining pro-social get-up-and-go, envisaging de-energised patients satisfied with easy lives of
comfy sofas and daytime TV. It doesn’t help assuage critics that to curb illegal opiate use, methadone doses need to be high overall, or at
least high enough for that patient; half-hearted maintenance with one eye on keeping doses low to ease future withdrawal does not work
as well.
The title of our hot topic entry, Ever controversial: prescribing opiates to opiate addicts, captures the essence of the controversy. For some
it goes violently against the grain to give addicts the very type of drug to which they have become addicted, but doing this works so well
precisely because it goes with the grain of addiction. Rather than attacking this head on, it harnesses the patient’s dependence to attract
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and hold like no other treatment, and can then be used to bend, nudge, or insist on broader improvements (see Highlighted study), or just
allow these to emerge as patients are relieved of the all-encompassing roller-coaster of addiction to a short-acting, illegally obtained,
injected drug.
The hot topic entry more fully describes the controversy, culminating for the moment with English and Scottish expert reports. Among
other things, both faced down the strong ‘new recovery’ push from government to curtail methadone maintenance, so that in all but
exceptional circumstances, it would no longer be ‘maintenance’, but more like the detoxification option in the Highlighted study.
Do you agree with the entry’s conclusion that because opposing camps value different things, evidence alone will not decide the future of
maintenance prescribing? Ask yourself, can maintenance ever be broadly accepted unless it becomes seen as a route to abstinence for
the majority? Should we relegate its indefinite application to a fallback position when reaching for abstinence seems impossible or too
risky? – the line taken by the 1926 Rolleston report which legitimated what we now know as maintenance. Or is indefinite maintenance
as valid an outcome as being ‘drug-free’, one which should “not be considered a failure”, in the words of the Scottish report. Perhaps you
feel closer to the English version, which saw it as second best in a process which should strive to “move towards a drug-free lifestyle”. At
the culmination of this centuries-long debate, where do you stand?
 Do opiate-blocking implants make things too easy? This discussion ends with “the curious possibility that precisely because a
technology is (relatively) effortlessly effective, it is to that degree under suspicion.” Let’s see how we get there.
Under Where should I start? we spoke of the “hopes and expectations of techno-medical fixes” to addiction, so far largely a history of
dead-ends and disappointments. A key problem is that the more effective a medication in preventing drug use, the more patients
dependent on that drug simply refuse to take it or quickly abandon the treatment. That has been the fate of naltrexone, meaning that in
practice this opiate-blocking medication promotes abstinence no better than a placebo. But what if we can make it impossible for
patients to stop taking it, preventing later temptations betraying their initial resolve? That is the promise of naltrexone implants
(surgically inserted in flesh under the skin) and depot injections, which block the effects of heroin for up to several months, and are
impossible or extremely difficult for patients to remove.
The fact that Russia outlaws opiate substitute prescribing made it an ideal site for one of the key trials. After detoxification, 306 patients
were offered 24 weeks of implants (renewed every two months) and daily pills – each had to take both. Some were randomly allocated an
active naltrexone implant, some to active naltrexone pills, and some to inactive forms of both, but none were told which. (Coincidentally,
the trial reflected the impact of Russia’s rejection of harm reduction and methadone. Virtually all study participants were infected with
hepatitis C and nearly half with HIV.)
Check the free report on the trial. You will see that by the end, without an active implant just handfuls of the patients were still in
treatment and had not relapsed to heroin use, compared to just over half with the active implant, which also led to significantly more
urine tests verifying patients had not taken heroin. In contrast, active pills were only marginally more effective than placebos. Results of
a similar Australian trial and others cited in our commentary on an earlier Russian study confirm the advantages of long-acting naltrexone
implants and injections over the oral drug and over offering no medication at all, making these seem a godsend for patients motivated to
return to a life without opiate-type drugs, including prescribed substitutes.
Why then, aren’t we using them more? There are cost, regulatory (they are not approved medications in the UK), and minor safety
considerations, the need for patients to be absolutely clear of opiate-type drugs before starting treatment, and the general antipathy in
some (especially 12-step) quarters and by some patients to taking anything that looks like a drug. However, surely more lies behind the
cursory mentions of these technologies in our starting point review and latest UK guidance.
The guidance hints at one reason; opiate-blocking implants/injections might make it too easy to stay (more or less) abstinent from
opiates. If that seems incredible, here’s what it says about their possible role in abstinence-oriented rehabilitation programmes: “Is a
resident to whom a long-acting naltrexone formulation has been administered somehow going against the ethos – and the interests of
other residents – of a programme that lays great store on (and expects of its other residents) strength of will and the ability to resist
temptation in the absence of any medicinal support?” Fixing the problem with a single (or even several) implants seems light years from
understandings of addiction as a deeply rooted psychological and social condition requiring life-transforming change.
Against the yardstick of a consensus UK definition, a ‘recovery’ programme which just stops the user taking their accustomed drug is not
recovery at all. It falls at the first hurdle of being “voluntarily-sustained control over substance use”; the implant is doing the controlling,
not the patient. Then it does not in itself do anything “which maximises health and wellbeing and participation in the rights, roles and
responsibilities of society”. In fact, it might make these broader changes less likely because they are no longer needed to bolster
abstinence. Even the patients insist recovery “requires effort and is not signified by easy gains. On the contrary, recovery will likely hurt
and cause pain.” Do we face here the curious possibility that precisely because a technology is (relatively) effortlessly effective, it is to
that degree under suspicion? And is this reminiscent of the reasons which make some suspicious of an opposing technology, long-term
maintenance not on opiate blockers, but on opiate-type drugs themselves?
Thanks for their comments on this entry in draft to Colin Brewer and to John Strang of the National Addiction Centre in London, England. Commentators bear no
responsibility for the text including the interpretations and any remaining errors.
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